|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,852 JPY | -0.16% |
|
-1.40% | -9.17% |
| Apr. 25 | Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5% | MT |
| Apr. 24 | Chugai Pharmaceutical's Profit Slightly Up in Q1 | MT |
TOKYO (Reuters) - A Japanese health ministry panel approved the expanded use of Chugai Pharmaceutical Co's COVID-19 antibody treatment to allow for preventative care, local media reported on Thursday.
Japanese regulators approved Chugai's antibody cocktail, known as Ronapreve, as a treatment for COVID-19 in July.
Chugai applied last month to allow the use of the drug as prophylaxis for COVID-19 and as treatment of asymptomatic cases.
(Reporting by Daniel Leussink; Editing by Toby Chopra)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.17% | 51.41B | |
| +25.40% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +12.98% | 233B | |
| +5.31% | 201B | |
| -9.98% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
CHUGAI PHARMACEUTICAL CO., LTD 
